Long-term cardiac follow-up in survivors of a malignant bone tumour

Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15–27.5) post-treatment. Age at follow-up was 39 years (range 27–59) and cumulative dose of doxorubicin was 360 mg/m2 (range 225–550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. Results: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. Conclusions: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.